EUVIMEDEUVIMED entdecken
Crossref

LC–MS/MS–Based Serum Lipidomic Profile to Reveal Cancer‐Specific Biomarkers for Renal Cell Carcinoma

Lin Lin iD, Jiaxin Zheng, Sixia Hu

Biomedical Chromatography · 2025

DOI: 10.1002/bmc.70230 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical Chromatography, 2025. Verfasst von Lin Lin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Sustech Core Research Facilities, Southern University of Science and Technology, Shenzhen, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Tandem Mass Spectrometry, Kidney Neoplasms, Biomarkers, Tumor. Die Arbeit nennt 56 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Renal cell carcinoma (RCC) is one of the most lethal malignant tumors in the urinary system, and its incidence rate is increasing in the last decade. Discovering sensitive and specific biomarkers for RCC and exploring its pathogenesis are of great clinical significance. Here, a liquid chromatography–tandem mass spectrometry (LC–MS/MS) based serum lipidomic profile was carried out to reveal the lipid expression differences in RCC patients and healthy controls. A total of 112 participants were enrolled in the training set, including nonmalignant disease subjects for specific screening. As a result, 66 RCC‐specific lipid variables were screened and further validated with an independent test set. Receiver operating characteristic (ROC) analysis was used to evaluate the clinical diagnostic potential of the biomarkers. Twenty‐four of them were found to have AUC (area under the curve) values larger than 0.85, and 13 of them were clearly identified. The study indicated reduced lysophosphatidylcholine (LPC) serum levels and increased triglyceride (TG) levels in RCC patients, which might be developed as a potential therapeutic target for cancer treatment. A biomarker pattern composed of TG (19:1/18:2/18:2) and TG (18:0/16:0/16:0) was discovered to have the highest AUC value of 0.995, with a sensitivity and specificity up to 97.6% and 95.0%, respectively.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellTandem Mass SpectrometryKidney NeoplasmsBiomarkers, TumorLipidomicsLipidsHumansMaleFemaleMiddle AgedChromatography, LiquidAdultAgedROC CurveReproducibility of ResultsCase-Control StudiesLiquid Chromatography-Mass Spectrometry

Stichwörter der Autor:innen

biomarkerlipidomicsliquid chromatography–tandem mass spectrometry (LC–MS/MS)renal cell carcinoma

Substanzen

Biomarkers, TumorLipids

Autor:innen und Institutionen

  • Sustech Core Research Facilities, Southern University of Science and Technology, Shenzhen, China.
  • Department of Urology, The First Affiliated Hospital of Xiamen University, Xiamen, China.

ORCID-Profile: Lin Lin

Zitieren

APA

Lin, L., Zheng, J., & Hu, S. (2025). LC–MS/MS–Based Serum Lipidomic Profile to Reveal Cancer‐Specific Biomarkers for Renal Cell Carcinoma. Biomedical Chromatography. https://doi.org/10.1002/bmc.70230

Vancouver

Lin L, Zheng J, Hu S. LC–MS/MS–Based Serum Lipidomic Profile to Reveal Cancer‐Specific Biomarkers for Renal Cell Carcinoma. Biomedical Chromatography. 2025. doi:10.1002/bmc.70230

BibTeX
@article{Lin2025,
  author = {Lin, Lin and Zheng, Jiaxin and Hu, Sixia},
  title = {LC–MS/MS–Based Serum Lipidomic Profile to Reveal Cancer‐Specific Biomarkers for Renal Cell Carcinoma},
  journal = {Biomedical Chromatography},
  year = {2025},
  doi = {10.1002/bmc.70230}
}
Kostenlos starten →